Corrigendum to “Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial” [Gynecologic Oncology 161 (2021) 143–151]

Janda, Monika; Robledo, Kristy; Gebski, Val; Armes, Jane E.; Alizart, Michelle; Brennan, Donal J.; Cummings, Margaret C.; Chen, Chen; Leung, Yee; Sykes, Peter; McNally, Orla; Oehler, Martin K.; GraemeWalker,; Garrett, Andrea; Land, Russell; Nicklin, James L.; Chetty, Naven; Perrin, Lewis; Hoet, Greet; Sowden, Katherine; Eva, Lois; Tristram, Amanda; Obermair, Andreas

doi:10.1016/j.ygyno.2021.05.016

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, the 52‐mg LNG IUD decreases endometrial hyperplasia and polyposis in women exposed to estradiol receptor modulators (such as tamoxifen) 25‐31 . The feMMe clinical trial 32 from Australia and New Zealand studied the effect of the LNG‐IUD to manage histologically confirmed endometrial adenocarcinoma and endometrial hyperplasia with atypia confined to the uterus in women with body mass index greater than 30 who wished to maintain fertility or were at high risk of surgical complications due to severe comorbidities. The study found a response rate of 67% following LNG‐IUD with weight loss (7% body weight by 6 months); 61% with LNG‐IUD alone; and 57% with LNG‐IUD with metformin (500 mg orally twice daily).…”

Section: Endometrial Cancermentioning

confidence: 99%

Contraceptive strategies for reducing the risk of reproductive cancers

Aliabadi,

Wilailak,

McNally

et al. 2024

Intl J Gynecology & Obste

Self Cite

View full text Add to dashboard Cite

Reproductive cancers, encompassing various malignancies like endometrial, ovarian, cervical cancer, and gestational trophoblastic neoplasia, pose a significant global health burden. Understanding their patterns is vital for effective prevention and management. Contraceptives show a protective effect against some of these cancers. This clinical guidance document aims to elucidate the disease burden of reproductive cancers and the evidence supporting contraceptive methods in prevention and management. Regional disparities in incidence and mortality highlight the urgent need for targeted interventions, particularly in low‐resource settings. Healthcare providers must weigh individual risk profiles and medical eligibility criteria when discussing contraceptive options. Enhanced health literacy through direct patient education is essential for leveraging low‐cost behavioral interventions to mitigate reproductive cancer risks.

show abstract

Section: Endometrial Cancermentioning

confidence: 99%

Contraceptive strategies for reducing the risk of reproductive cancers

Aliabadi,

Wilailak,

McNally

et al. 2024

Intl J Gynecology & Obste

Self Cite

View full text Add to dashboard Cite

show abstract

Age as a Predictor of Time to Response for Patients Undergoing Medical Management of Endometrial Cancer

Carolyn R,

Wendy Y

et al. 2023

Clin J Obstet Gynecol

View full text Add to dashboard Cite

Objective: To explore the pathologic response rate to primary progesterone treatment in patients with Endometrial Intraepithelial Neoplasia (EIN) and early-stage endometrioid-type Endometrial Adenocarcinoma (EAC). Methods: Retrospective chart data were collected for patients with either EIN or EAC receiving primary progesterone treatment between 2015 and 2022. The presence of complete or partial response, time to response, and other demographic and treatment factors were recorded to determine independent predictors of response to progestin treatment. Results: In total, 112 women who were diagnosed with EIN or EAC were treated with upfront progestin therapy, of whom 79 had sufficient follow-up to assess response. Fifty patients (63%) responded, of whom 10 (20%) ultimately relapsed. Response was more robust among patients with EIN (79%, n = 33) compared with patients who had cancer (46%, n = 17). The median time to respond was 5.8 months overall. Diagnosis of EIN, younger age at diagnosis, and any pathologic evidence of progesterone effect were all predictors of treatment response. Younger patients had a significantly shorter time to partial or complete response with a median time to response of 5.9 months in patients ≤ 45 and 13.8 months in patients > 45. Conclusion: Our study demonstrated a lower overall response rate (63%) than reported in previous studies, especially for patients with cancer (46%). Younger patients had a significantly shorter time to respond than older patients. Pathologic progesterone effect observed at any time during treatment was a significant predictor of treatment response regardless of diagnosis and could serve as an early predictor of response to therapy.

show abstract

Corrigendum to “Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial” [Gynecologic Oncology 161 (2021) 143–151]

Cited by 2 publications

References 0 publications

Contraceptive strategies for reducing the risk of reproductive cancers

Contraceptive strategies for reducing the risk of reproductive cancers

Age as a Predictor of Time to Response for Patients Undergoing Medical Management of Endometrial Cancer

Contact Info

Product

Resources

About